$322 Million is the total value of Foresite Capital Management V, LLC's 17 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BCTG | Exit | BCTG Acquisition Corp. | $0 | – | -400,000 | -100.0% | -1.79% | – |
ALXO | Exit | ALX Oncology Holdings Inc. | $0 | – | -231,200 | -100.0% | -4.97% | – |
RLAY | Exit | Relay Therapeutics, Inc. | $0 | – | -400,000 | -100.0% | -5.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-05 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
4 | 2023-08-31 |
13F-HR | 2023-08-11 |
4 | 2023-07-19 |
13F-HR | 2023-05-12 |
4 | 2023-05-10 |
4 | 2023-04-06 |
4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.